BLRX
BioLineRx Delivers Strong Q1 2026 Performance, Initiates Pivotal GLIX1 Trial for Glioblastoma
Jerusalem, Israel - May 27, 2026 BioLineRx, a leading developer of novel therapeutic solutions for major unmet medical needs, reported strong financial results for the first quarter (Q1) of 2026. The company's quarterly performance was highlighted by the initiation of a pivotal phase I/IIa clinical trial for